Humanized antibody specific for tumor necrosis factor-alpha
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 12, 2010
Grant Date -
Jan 10, 2008
app pub date -
Dec 29, 2005
filing date -
Dec 29, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Humanized antibodies specifically binding to hTNF-α are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-α-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully